For everything medicine has yet to become
NEUVIOR is a pharmaceutical research and technology company bringing scientific imagination to the decisions, discoveries, and resources that shape medicine.
Our work spans medicines intelligence, biological and therapeutic research, and the materials and energy behind pharmaceutical production. We bring together people who enjoy difficult questions and care about what an answer makes possible.
Ingenuity and the art of possibility
Medicine carries generations of knowledge, persistence, and invention. We want to build on that inheritance with the freedom to ask what could come next, and the care to examine each idea in detail.
A programme might begin with a medicines decision, a cell that survives treatment, or a material used in manufacturing. We follow the question towards a useful outcome: a technology people can use, an intervention worth developing, or a better way to produce what medicine needs.
Three fields of work
Medicines Intelligence
Our technology centre, home to PHARMORIS and research into medicines implementation, economic value, regulatory intelligence, and pharmaceutical data.
Biomedical Research
The home for biological and therapeutic research, with glioblastoma as the initial focus through 2030.
Regenerative Economics
Where we dive into pharmaceutical materials, energy, circular production, and related industrial research.
What’s going on
PHARMORIS connects medicines evidence with the decisions and practical work needed to realise value. Our glioblastoma programme investigates the contribution of treatment-surviving cells to recurrence. ZYLON and PHARMORIS-ECO examine materials, resource recovery, and energy use in pharmaceutical manufacturing.
Each programme has a distinct question and a route towards the evidence its next decision requires.
- AI Ethics Now / University of Warwick IATL. Podcast appearance. AI and Accountability: When Does a Suggestion Become a Decision?.
- Pharmaphorum. Contributed analysis. Approval is not access: Pilots' real test is implementation.
- TechRadar Pro. Contributed opinion. Five questions to test whether an AI stack is truly under your control.
- ET Pharma. Founder commentary. India’s pharma quality reset will be won after the inspector leaves.
- Financial Times. Founder letter. Letter: The real test is whether invention leads to adoption.
- Pharmaceutical Technology. Founder viewpoint. Why the India UK trade deal now needs a five gate implementation ledger.
- SekberNews. Derivative coverage. India UK Pharma Trade Deal: Moving Beyond Tariff Reductions.
The environments that could take medicine further
NEUVIOR’s campus programme explores the scientific environments that future medicines development could need. The Glasgow and Hyderabad pathways bring formulation, analytical science, digital operations, and infrastructure planning into a shared development ambition, whilst each location retains its own technical and commercial case.
The work is at predevelopment stage. Its purpose is to establish which capabilities would be useful, who would use them, and what would justify investment.
A company built around people
“However far upstream we work, we never lose sight of the life at the other end.”Varun Sharma, Founder and CEO
We welcome researchers, healthcare teams, industrial partners, and investors who see a useful connection with our work.